Influence of ibuprofen-arginine on serum levels of nitric oxide metabolites in patients with chronic lower back pain: a single-blind, placebo-controlled pilot trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN18723747

Enrollment

Registered

2006-02-17

Start date

2003-03-04

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lower back pain Injury, Occupational Diseases, Poisoning Lower back pain

Interventions

Ibuprofen-arginine 400 mg (verum) was administered orally once.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Non-specific chronic lower back pain (Visual Analogue Scale [VAS] greater than or equal to 60).

Exclusion criteria

Exclusion criteria: Specific lower back pain.

Design outcomes

Primary

Measure	Time frame
No metabolites.	—

Secondary

Measure	Time frame
Pain intensity (VAS).	—

Countries

Switzerland

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026